The global Rapamycin-Eluting Coronary Stent System market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

A Rapamycin-Eluting Coronary Stent System is a medical device used to treat narrowed or blocked coronary arteries. The system consists of a stent coated with the drug sirolimus. The stent is implanted into the coronary artery, providing mechanical support to keep the vessel open and prevent restenosis. Sirolimus, an immunosuppressant, inhibits the proliferation of endothelial cells, thereby reducing the risk of restenosis after stent implantation. The sirolimus-eluting coronary stent system effectively maintains blood flow and reduces the likelihood of needing further interventions.

From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Rapamycin-Eluting Coronary Stent System leading manufacturers including Q3 Medical, Shandong Huaan Biotechnology, MicroPort, Lepu, Shandong Jiwei Medical, OrbusNeich Medical, Micell Technologies Ireland, Cardionovum, etc., dominate supply; the top five capture approximately % of global revenue, with Q3 Medical leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Rapamycin-Eluting Coronary Stent System market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Rapamycin-Eluting Coronary Stent System Market Report

Report Metric	Details
Report Name	Rapamycin-Eluting Coronary Stent System Market
Segment by Type	Bioresorbable Stents Traditional Metal Stents
Segment by Application	Hospital Clinic
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Q3 Medical, Shandong Huaan Biotechnology, MicroPort, Lepu, Shandong Jiwei Medical, OrbusNeich Medical, Micell Technologies Ireland, Cardionovum
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Rapamycin-Eluting Coronary Stent System study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Rapamycin-Eluting Coronary Stent System Market report?

Ans: The main players in the Rapamycin-Eluting Coronary Stent System Market are Q3 Medical, Shandong Huaan Biotechnology, MicroPort, Lepu, Shandong Jiwei Medical, OrbusNeich Medical, Micell Technologies Ireland, Cardionovum

What are the Application segmentation covered in the Rapamycin-Eluting Coronary Stent System Market report?

Ans: The Applications covered in the Rapamycin-Eluting Coronary Stent System Market report are Hospital, Clinic

What are the Type segmentation covered in the Rapamycin-Eluting Coronary Stent System Market report?

Ans: The Types covered in the Rapamycin-Eluting Coronary Stent System Market report are Bioresorbable Stents, Traditional Metal Stents

1 Study Coverage

1.1 Introduction to Rapamycin-Eluting Coronary Stent System: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Rapamycin-Eluting Coronary Stent System Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Bioresorbable Stents

1.2.3 Traditional Metal Stents

1.3 Market Segmentation by Application

1.3.1 Global Rapamycin-Eluting Coronary Stent System Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Rapamycin-Eluting Coronary Stent System Revenue Estimates and Forecasts 2020-2031

2.2 Global Rapamycin-Eluting Coronary Stent System Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Rapamycin-Eluting Coronary Stent System Sales Estimates and Forecasts 2020-2031

2.4 Global Rapamycin-Eluting Coronary Stent System Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Rapamycin-Eluting Coronary Stent System Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Rapamycin-Eluting Coronary Stent System Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Bioresorbable Stents Market Size by Manufacturers

3.5.2 Traditional Metal Stents Market Size by Manufacturers

3.6 Global Rapamycin-Eluting Coronary Stent System Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Rapamycin-Eluting Coronary Stent System Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Rapamycin-Eluting Coronary Stent System Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Rapamycin-Eluting Coronary Stent System Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Rapamycin-Eluting Coronary Stent System Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Rapamycin-Eluting Coronary Stent System Sales and Revenue by Type (2020-2031)

6.4 North America Rapamycin-Eluting Coronary Stent System Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Rapamycin-Eluting Coronary Stent System Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Rapamycin-Eluting Coronary Stent System Sales and Revenue by Type (2020-2031)

7.4 Europe Rapamycin-Eluting Coronary Stent System Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Rapamycin-Eluting Coronary Stent System Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Rapamycin-Eluting Coronary Stent System Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Rapamycin-Eluting Coronary Stent System Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Rapamycin-Eluting Coronary Stent System Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Rapamycin-Eluting Coronary Stent System Sales and Revenue by Type (2020-2031)

9.4 Central and South America Rapamycin-Eluting Coronary Stent System Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Rapamycin-Eluting Coronary Stent System Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Rapamycin-Eluting Coronary Stent System Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Rapamycin-Eluting Coronary Stent System Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Rapamycin-Eluting Coronary Stent System Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Q3 Medical

11.1.1 Q3 Medical Corporation Information

11.1.2 Q3 Medical Business Overview

11.1.3 Q3 Medical Rapamycin-Eluting Coronary Stent System Product Models, Descriptions and Specifications

11.1.4 Q3 Medical Rapamycin-Eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Q3 Medical Rapamycin-Eluting Coronary Stent System Sales by Product in 2024

11.1.6 Q3 Medical Rapamycin-Eluting Coronary Stent System Sales by Application in 2024

11.1.7 Q3 Medical Rapamycin-Eluting Coronary Stent System Sales by Geographic Area in 2024

11.1.8 Q3 Medical Rapamycin-Eluting Coronary Stent System SWOT Analysis

11.1.9 Q3 Medical Recent Developments

11.2 Shandong Huaan Biotechnology

11.2.1 Shandong Huaan Biotechnology Corporation Information

11.2.2 Shandong Huaan Biotechnology Business Overview

11.2.3 Shandong Huaan Biotechnology Rapamycin-Eluting Coronary Stent System Product Models, Descriptions and Specifications

11.2.4 Shandong Huaan Biotechnology Rapamycin-Eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Shandong Huaan Biotechnology Rapamycin-Eluting Coronary Stent System Sales by Product in 2024

11.2.6 Shandong Huaan Biotechnology Rapamycin-Eluting Coronary Stent System Sales by Application in 2024

11.2.7 Shandong Huaan Biotechnology Rapamycin-Eluting Coronary Stent System Sales by Geographic Area in 2024

11.2.8 Shandong Huaan Biotechnology Rapamycin-Eluting Coronary Stent System SWOT Analysis

11.2.9 Shandong Huaan Biotechnology Recent Developments

11.3 MicroPort

11.3.1 MicroPort Corporation Information

11.3.2 MicroPort Business Overview

11.3.3 MicroPort Rapamycin-Eluting Coronary Stent System Product Models, Descriptions and Specifications

11.3.4 MicroPort Rapamycin-Eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 MicroPort Rapamycin-Eluting Coronary Stent System Sales by Product in 2024

11.3.6 MicroPort Rapamycin-Eluting Coronary Stent System Sales by Application in 2024

11.3.7 MicroPort Rapamycin-Eluting Coronary Stent System Sales by Geographic Area in 2024

11.3.8 MicroPort Rapamycin-Eluting Coronary Stent System SWOT Analysis

11.3.9 MicroPort Recent Developments

11.4 Lepu

11.4.1 Lepu Corporation Information

11.4.2 Lepu Business Overview

11.4.3 Lepu Rapamycin-Eluting Coronary Stent System Product Models, Descriptions and Specifications

11.4.4 Lepu Rapamycin-Eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Lepu Rapamycin-Eluting Coronary Stent System Sales by Product in 2024

11.4.6 Lepu Rapamycin-Eluting Coronary Stent System Sales by Application in 2024

11.4.7 Lepu Rapamycin-Eluting Coronary Stent System Sales by Geographic Area in 2024

11.4.8 Lepu Rapamycin-Eluting Coronary Stent System SWOT Analysis

11.4.9 Lepu Recent Developments

11.5 Shandong Jiwei Medical

11.5.1 Shandong Jiwei Medical Corporation Information

11.5.2 Shandong Jiwei Medical Business Overview

11.5.3 Shandong Jiwei Medical Rapamycin-Eluting Coronary Stent System Product Models, Descriptions and Specifications

11.5.4 Shandong Jiwei Medical Rapamycin-Eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Shandong Jiwei Medical Rapamycin-Eluting Coronary Stent System Sales by Product in 2024

11.5.6 Shandong Jiwei Medical Rapamycin-Eluting Coronary Stent System Sales by Application in 2024

11.5.7 Shandong Jiwei Medical Rapamycin-Eluting Coronary Stent System Sales by Geographic Area in 2024

11.5.8 Shandong Jiwei Medical Rapamycin-Eluting Coronary Stent System SWOT Analysis

11.5.9 Shandong Jiwei Medical Recent Developments

11.6 OrbusNeich Medical

11.6.1 OrbusNeich Medical Corporation Information

11.6.2 OrbusNeich Medical Business Overview

11.6.3 OrbusNeich Medical Rapamycin-Eluting Coronary Stent System Product Models, Descriptions and Specifications

11.6.4 OrbusNeich Medical Rapamycin-Eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 OrbusNeich Medical Recent Developments

11.7 Micell Technologies Ireland

11.7.1 Micell Technologies Ireland Corporation Information

11.7.2 Micell Technologies Ireland Business Overview

11.7.3 Micell Technologies Ireland Rapamycin-Eluting Coronary Stent System Product Models, Descriptions and Specifications

11.7.4 Micell Technologies Ireland Rapamycin-Eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Micell Technologies Ireland Recent Developments

11.8 Cardionovum

11.8.1 Cardionovum Corporation Information

11.8.2 Cardionovum Business Overview

11.8.3 Cardionovum Rapamycin-Eluting Coronary Stent System Product Models, Descriptions and Specifications

11.8.4 Cardionovum Rapamycin-Eluting Coronary Stent System Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Cardionovum Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Rapamycin-Eluting Coronary Stent System Industry Chain

12.2 Rapamycin-Eluting Coronary Stent System Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Rapamycin-Eluting Coronary Stent System Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Rapamycin-Eluting Coronary Stent System Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Rapamycin-Eluting Coronary Stent System Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Rapamycin-Eluting Coronary Stent System Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Q3 Medical

Shandong Huaan Biotechnology

Shandong Jiwei Medical

Micell Technologies Ireland

List of Tables

Table 1. Global Rapamycin-Eluting Coronary Stent System Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Rapamycin-Eluting Coronary Stent System Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Rapamycin-Eluting Coronary Stent System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Rapamycin-Eluting Coronary Stent System Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Rapamycin-Eluting Coronary Stent System Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Rapamycin-Eluting Coronary Stent System Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global Rapamycin-Eluting Coronary Stent System Sales by Region (2020-2025) & (K Units)

Table 8. Global Rapamycin-Eluting Coronary Stent System Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Rapamycin-Eluting Coronary Stent System Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global Rapamycin-Eluting Coronary Stent System Sales Share by Manufacturers (2020-2025)

Table 12. Global Rapamycin-Eluting Coronary Stent System Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Rapamycin-Eluting Coronary Stent System Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Rapamycin-Eluting Coronary Stent System by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rapamycin-Eluting Coronary Stent System as of 2024)

Table 16. Global Rapamycin-Eluting Coronary Stent System Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Rapamycin-Eluting Coronary Stent System Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers Rapamycin-Eluting Coronary Stent System Manufacturing Base and Headquarters

Table 19. Global Rapamycin-Eluting Coronary Stent System Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Rapamycin-Eluting Coronary Stent System Sales by Type (2020-2025) & (K Units)

Table 23. Global Rapamycin-Eluting Coronary Stent System Sales by Type (2026-2031) & (K Units)

Table 24. Global Rapamycin-Eluting Coronary Stent System Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Rapamycin-Eluting Coronary Stent System Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Rapamycin-Eluting Coronary Stent System ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Rapamycin-Eluting Coronary Stent System Sales by Application (2020-2025) & (K Units)

Table 29. Global Rapamycin-Eluting Coronary Stent System Sales by Application (2026-2031) & (K Units)

Table 30. Rapamycin-Eluting Coronary Stent System High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Rapamycin-Eluting Coronary Stent System Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Rapamycin-Eluting Coronary Stent System Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Rapamycin-Eluting Coronary Stent System ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Rapamycin-Eluting Coronary Stent System Growth Accelerators and Market Barriers

Table 37. North America Rapamycin-Eluting Coronary Stent System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Rapamycin-Eluting Coronary Stent System Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Rapamycin-Eluting Coronary Stent System Growth Accelerators and Market Barriers

Table 40. Europe Rapamycin-Eluting Coronary Stent System Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Rapamycin-Eluting Coronary Stent System Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Rapamycin-Eluting Coronary Stent System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Rapamycin-Eluting Coronary Stent System Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Rapamycin-Eluting Coronary Stent System Growth Accelerators and Market Barriers

Table 45. Southeast Asia Rapamycin-Eluting Coronary Stent System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Rapamycin-Eluting Coronary Stent System Investment Opportunities and Key Challenges

Table 47. Central and South America Rapamycin-Eluting Coronary Stent System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Rapamycin-Eluting Coronary Stent System Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Rapamycin-Eluting Coronary Stent System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Q3 Medical Corporation Information

Table 51. Q3 Medical Description and Major Businesses

Table 52. Q3 Medical Product Models, Descriptions and Specifications

Table 53. Q3 Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Q3 Medical Sales Value Proportion by Product in 2024

Table 55. Q3 Medical Sales Value Proportion by Application in 2024

Table 56. Q3 Medical Sales Value Proportion by Geographic Area in 2024

Table 57. Q3 Medical Rapamycin-Eluting Coronary Stent System SWOT Analysis

Table 58. Q3 Medical Recent Developments

Table 59. Shandong Huaan Biotechnology Corporation Information

Table 60. Shandong Huaan Biotechnology Description and Major Businesses

Table 61. Shandong Huaan Biotechnology Product Models, Descriptions and Specifications

Table 62. Shandong Huaan Biotechnology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Shandong Huaan Biotechnology Sales Value Proportion by Product in 2024

Table 64. Shandong Huaan Biotechnology Sales Value Proportion by Application in 2024

Table 65. Shandong Huaan Biotechnology Sales Value Proportion by Geographic Area in 2024

Table 66. Shandong Huaan Biotechnology Rapamycin-Eluting Coronary Stent System SWOT Analysis

Table 67. Shandong Huaan Biotechnology Recent Developments

Table 68. MicroPort Corporation Information

Table 69. MicroPort Description and Major Businesses

Table 70. MicroPort Product Models, Descriptions and Specifications

Table 71. MicroPort Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. MicroPort Sales Value Proportion by Product in 2024

Table 73. MicroPort Sales Value Proportion by Application in 2024

Table 74. MicroPort Sales Value Proportion by Geographic Area in 2024

Table 75. MicroPort Rapamycin-Eluting Coronary Stent System SWOT Analysis

Table 76. MicroPort Recent Developments

Table 77. Lepu Corporation Information

Table 78. Lepu Description and Major Businesses

Table 79. Lepu Product Models, Descriptions and Specifications

Table 80. Lepu Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Lepu Sales Value Proportion by Product in 2024

Table 82. Lepu Sales Value Proportion by Application in 2024

Table 83. Lepu Sales Value Proportion by Geographic Area in 2024

Table 84. Lepu Rapamycin-Eluting Coronary Stent System SWOT Analysis

Table 85. Lepu Recent Developments

Table 86. Shandong Jiwei Medical Corporation Information

Table 87. Shandong Jiwei Medical Description and Major Businesses

Table 88. Shandong Jiwei Medical Product Models, Descriptions and Specifications

Table 89. Shandong Jiwei Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Shandong Jiwei Medical Sales Value Proportion by Product in 2024

Table 91. Shandong Jiwei Medical Sales Value Proportion by Application in 2024

Table 92. Shandong Jiwei Medical Sales Value Proportion by Geographic Area in 2024

Table 93. Shandong Jiwei Medical Rapamycin-Eluting Coronary Stent System SWOT Analysis

Table 94. Shandong Jiwei Medical Recent Developments

Table 95. OrbusNeich Medical Corporation Information

Table 96. OrbusNeich Medical Description and Major Businesses

Table 97. OrbusNeich Medical Product Models, Descriptions and Specifications

Table 98. OrbusNeich Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. OrbusNeich Medical Recent Developments

Table 100. Micell Technologies Ireland Corporation Information

Table 101. Micell Technologies Ireland Description and Major Businesses

Table 102. Micell Technologies Ireland Product Models, Descriptions and Specifications

Table 103. Micell Technologies Ireland Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Micell Technologies Ireland Recent Developments

Table 105. Cardionovum Corporation Information

Table 106. Cardionovum Description and Major Businesses

Table 107. Cardionovum Product Models, Descriptions and Specifications

Table 108. Cardionovum Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Cardionovum Recent Developments

Table 110. Key Raw Materials Distribution

Table 111. Raw Materials Key Suppliers

Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 113. Milestones in Production Technology Evolution

Table 114. Distributors List

Table 115. Market Trends and Market Evolution

Table 116. Market Drivers and Opportunities

Table 117. Market Challenges, Risks, and Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

List of Figures

Figure 1. Rapamycin-Eluting Coronary Stent System Product Picture

Figure 2. Global Rapamycin-Eluting Coronary Stent System Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Bioresorbable Stents Product Picture

Figure 4. Traditional Metal Stents Product Picture

Figure 5. Global Rapamycin-Eluting Coronary Stent System Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Hospital

Figure 7. Clinic

Figure 8. Rapamycin-Eluting Coronary Stent System Report Years Considered

Figure 9. Global Rapamycin-Eluting Coronary Stent System Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 10. Global Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 11. Global Rapamycin-Eluting Coronary Stent System Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 12. Global Rapamycin-Eluting Coronary Stent System Revenue Market Share by Region (2020-2031)

Figure 13. Global Rapamycin-Eluting Coronary Stent System Sales (2020-2031) & (K Units)

Figure 14. Global Rapamycin-Eluting Coronary Stent System Sales (CAGR) by Region (2020-2031) (K Units)

Figure 15. Global Rapamycin-Eluting Coronary Stent System Sales Market Share by Region (2020-2031)

Figure 16. Top 5 and Top 10 Manufacturers Rapamycin-Eluting Coronary Stent System Sales Volume Market Share in 2024

Figure 17. Global Rapamycin-Eluting Coronary Stent System Revenue Market Share Ranking (2024)

Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 19. Bioresorbable Stents Revenue Market Share by Manufacturer in 2024

Figure 20. Traditional Metal Stents Revenue Market Share by Manufacturer in 2024

Figure 21. Global Rapamycin-Eluting Coronary Stent System Sales Market Share by Type (2020-2031)

Figure 22. Global Rapamycin-Eluting Coronary Stent System Revenue Market Share by Type (2020-2031)

Figure 23. Global Rapamycin-Eluting Coronary Stent System Sales Market Share by Application (2020-2031)

Figure 24. Global Rapamycin-Eluting Coronary Stent System Revenue Market Share by Application (2020-2031)

Figure 25. North America Rapamycin-Eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)

Figure 26. North America Rapamycin-Eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)

Figure 27. North America Top 5 Manufacturers Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) in 2024

Figure 28. North America Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Type (2020- 2031)

Figure 29. North America Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 30. North America Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)

Figure 31. North America Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)

Figure 32. US Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 33. Canada Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 34. Mexico Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 35. Europe Rapamycin-Eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)

Figure 36. Europe Rapamycin-Eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)

Figure 37. Europe Top 5 Manufacturers Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) in 2024

Figure 38. Europe Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Type (2020-2031)

Figure 39. Europe Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020-2031)

Figure 40. Europe Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)

Figure 41. Europe Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)

Figure 42. Germany Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 43. France Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 44. U.K. Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 45. Italy Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 46. Russia Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 47. Asia-Pacific Rapamycin-Eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)

Figure 48. Asia-Pacific Rapamycin-Eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)

Figure 49. Asia-Pacific Top 8 Manufacturers Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) in 2024

Figure 50. Asia-Pacific Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Type (2020- 2031)

Figure 51. Asia-Pacific Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 52. Asia-Pacific Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)

Figure 53. Asia-Pacific Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)

Figure 54. Indonesia Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 55. Japan Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 56. South Korea Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 57. China Taiwan Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 58. India Rapamycin-Eluting Coronary Stent System Revenue (2020-2031) & (US$ Million)

Figure 59. Central and South America Rapamycin-Eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)

Figure 60. Central and South America Rapamycin-Eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)

Figure 61. Central and South America Top 5 Manufacturers Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) in 2024

Figure 62. Central and South America Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Type (2021-2031)

Figure 63. Central and South America Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020-2031)

Figure 64. Central and South America Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)

Figure 65. Central and South America Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)

Figure 66. Brazil Rapamycin-Eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)

Figure 67. Argentina Rapamycin-Eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)

Figure 68. Middle East, and Africa Rapamycin-Eluting Coronary Stent System Sales YoY (2020-2031) & (K Units)

Figure 69. Middle East and Africa Rapamycin-Eluting Coronary Stent System Revenue YoY (2020-2031) & (US$ Million)

Figure 70. Middle East and Africa Top 5 Manufacturers Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) in 2024

Figure 71. Middle East and Africa Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Type (2021-2031)

Figure 72. South America Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Type (2020-2031)

Figure 73. Middle East and Africa Rapamycin-Eluting Coronary Stent System Sales Volume (K Units) by Application (2020-2031)

Figure 74. Middle East and Africa Rapamycin-Eluting Coronary Stent System Sales Revenue (US$ Million) by Application (2020-2031)

Figure 75. GCC Countries Rapamycin-Eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)

Figure 76. Turkey Rapamycin-Eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)

Figure 77. Egypt Rapamycin-Eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)

Figure 78. South Africa Rapamycin-Eluting Coronary Stent System Revenue (2020-2025) & (US$ Million)

Figure 79. Rapamycin-Eluting Coronary Stent System Industry Chain Mapping

Figure 80. Regional Rapamycin-Eluting Coronary Stent System Manufacturing Base Distribution (%)

Figure 81. Global Rapamycin-Eluting Coronary Stent System Production Market Share by Region (2020-2031)

Figure 82. Rapamycin-Eluting Coronary Stent System Production Process

Figure 83. Regional Rapamycin-Eluting Coronary Stent System Production Cost Structure

Figure 84. Channels of Distribution (Direct Vs Distribution)

Figure 85. Bottom-up and Top-down Approaches for This Report

Figure 86. Data Triangulation

Figure 87. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32P14840

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Point-of-care Troponin Testing Instrument Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22I19939

Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Troponin Analyzer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-38W19812

Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Anticoagulant Medications Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-39V16824

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions